Please select the option that best describes you:
Would you utilize OncotypeDX to guide decision making for a male with ER+ HER2- breast cancer and 1-3 positive sentinel lymph nodes?
Answer from: Medical Oncologist at Academic Institution
I would be wary of using Oncotype Dx to guide treatment decisions for males with 1-3 positive lymph nodes. If we learnt anything from the prospective RxPONDER data, it’s that the biology of tumors varies in different cohorts of HR+/HER2- breast cancer patients. The Recurrence Score (RS) algori...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
In a genomic profiling study of 59 male patients with breast cancer, 29% of samples were classified as luminal A–like and 71% as luminal B–like, with a heterogeneous repertoire of somatic genetic alterations. PIK3CA and TP53 mutations, and losses of 16q, which are typically see...
Answer from: Medical Oncologist at Community Practice
One of the findings in our study of Oncotype in men and women with ER-positive breast cancer-3,806 men and 571,115 women (Massarweh et al., PMID 29584547), is the distinct subgroups of Oncotype score in men vs women.Men had a more distinct subgroup with the very low Oncotype scores and another on th...